Personalis Expands Medicare Coverage for NeXT Personal to Pre-Surgical Breast Cancer Monitoring
Event summary
- Personalis' NeXT Personal MRD test secured fourth Medicare coverage decision, expanding to pre-surgical treatment monitoring for Stage II-III TNBC and HER2+ breast cancer.
- Coverage based on PREDICT-DNA study results published in Journal of Clinical Oncology, showing ultrasensitive ctDNA monitoring outperforms traditional metrics.
- Test can detect cancer traces below 100 parts per million, a range missed by less sensitive MRD assays.
- Previous coverage focused on post-surgical recurrence surveillance; new decision extends use to neoadjuvant therapy monitoring.
The big picture
This expansion positions Personalis as a leader in pre-surgical cancer monitoring, aligning with the growing trend of personalized medicine in oncology. The Medicare coverage decision validates the clinical utility of ultrasensitive MRD testing, potentially setting a new standard for treatment response assessment in breast cancer. The company's ability to secure multiple coverage decisions demonstrates its growing influence in precision oncology.
What we're watching
- Clinical Adoption
- How quickly oncologists will integrate NeXT Personal into pre-surgical treatment protocols for breast cancer patients.
- Reimbursement Expansion
- Whether CMS will extend coverage to additional cancer types or treatment settings beyond breast cancer.
- Competitive Positioning
- The pace at which competitors develop ultrasensitive MRD tests capable of detecting cancer traces below 100 PPM.
Related topics